Alnylam Pharmaceuticals, Inc. Could Rise a Lot According to The Today’s Call Option Activity

 Alnylam Pharmaceuticals, Inc. Could Rise a Lot According to The Today's Call Option Activity

In today’s session Alnylam Pharmaceuticals, Inc. (ALNY) registered an unusually high (148) contracts volume of call trades. Someone, most probably a professional was a very active buyer of the November, 2016 call, expecting serious ALNY increase. With 148 contracts traded and 19644 open interest for the Nov, 16 contract, it seems this is a quite bullish bet. The option with symbol: ALNY161118C00040000 closed last at: $0.3 or 73.9% down. About 451,178 shares traded hands. Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) has declined 50.61% since April 5, 2016 and is downtrending. It has underperformed by 52.56% the S&P500.

Analysts await Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) to report earnings on November, 14. They expect $-1.20 EPS, down 31.87% or $0.29 from last year’s $-0.91 per share. After $-1.05 actual EPS reported by Alnylam Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts 14.29% negative EPS growth.

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Ratings Coverage

Out of 14 analysts covering Alnylam Pharmaceuticals (NASDAQ:ALNY), 8 rate it a “Buy”, 0 “Sell”, while 6 “Hold”. This means 57% are positive. Alnylam Pharmaceuticals has been the topic of 29 analyst reports since August 7, 2015 according to StockzIntelligence Inc. The firm has “Market Outperform” rating by JMP Securities given on Wednesday, March 9. The rating was maintained by Piper Jaffray on Monday, August 31 with “Overweight”. The rating was downgraded by Barclays Capital on Thursday, October 6 to “Equal-Weight”. The rating was downgraded by JP Morgan to “Neutral” on Friday, August 7. Jefferies maintained it with “Buy” rating and $58 target price in Thursday, October 6 report. The rating was maintained by FBR Capital on Thursday, October 6 with “Outperform”. As per Thursday, October 6, the company rating was downgraded by Leerink Swann. The firm earned “Outperform” rating on Tuesday, May 3 by Leerink Swann. FBR Capital initiated the stock with “Outperform” rating in Tuesday, August 11 report. Stifel Nicolaus maintained Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) on Thursday, October 6 with “Hold” rating.

According to Zacks Investment Research, “Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company developing novel therapeutics based on RNA interference, or RNAi. The company is applying its therapeutic expertise in RNAi to address significant medical needs, many of which cannot effectively be addressed with small molecules or antibodies, the current major classes of drugs. Alnylam is building a pipeline of RNAi therapeutics; its lead program is in Phase I human clinical trials for the treatment of respiratory syncytial virus infection, which is the leading cause of hospitalization in infants in the U.S. The company’s leadership position in fundamental patents, technology, and know-how relating to RNAi has enabled it to form major alliances with leading companies including Merck, Medtronic, Novartis, and Biogen Idec.”

Insitutional Activity: The institutional sentiment decreased to 1.27 in 2016 Q2. Its down 0.21, from 1.48 in 2016Q1. The ratio turned negative, as 31 funds sold all Alnylam Pharmaceuticals, Inc. shares owned while 60 reduced positions. 23 funds bought stakes while 93 increased positions. They now own 72.84 million shares or 2.29% more from 71.20 million shares in 2016Q1.
Commerzbank Aktiengesellschaft Fi reported 4,357 shares or 0% of all its holdings. Commonwealth Savings Bank Of Aus accumulated 0% or 300 shares. Axa reported 125,662 shares or 0.03% of all its holdings. Hsbc Holding Public Ltd Liability Com reported 9,896 shares or 0% of all its holdings. Blackrock Grp holds 557,458 shares or 0.02% of its portfolio. Swiss Fincl Bank accumulated 214,900 shares or 0.02% of the stock. Diam Limited reported 44,878 shares or 0.04% of all its holdings. Arrowpoint Asset Mgmt Ltd has 0.42% invested in the company for 371,550 shares. Shell Asset Mngmt last reported 3,345 shares in the company. The New Hampshire-based Hemenway Tru Communication Ltd Liability Company has invested 0.19% in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY). Goldman Sachs Grp Inc, a New York-based fund reported 693,168 shares. Mitsubishi Ufj Tru Bk Corp holds 0.06% of its portfolio in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) for 469,756 shares. Marshall Wace Llp reported 34,727 shares or 0.02% of all its holdings. Teacher Retirement System Of Texas has invested 0% of its portfolio in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY). Da Davidson has invested 0% of its portfolio in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY).

Insider Transactions: Since July 19, 2016, the stock had 1 insider purchase, and 1 sale for $918,262 net activity. MARAGANORE JOHN sold 30,151 shares worth $1.95M. The insider PYOTT DAVID E I bought 27,900 shares worth $1.03 million.

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. The company has a market cap of $2.94 billion. The Firm is engaged in developing therapeutics based on ribonucleic acid interference (RNAi). It currently has negative earnings. The Firm is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate strategy for delivery of small interfering RNAs (siRNAs).

ALNY Company Profile

Alnylam Pharmaceuticals, Inc., incorporated on May 8, 2003, is a biopharmaceutical company. The Firm is engaged in developing therapeutics based on ribonucleic acid (RNA) interference (RNAi). The Firm is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate strategy for delivery of small interfering RNAs (siRNAs). The Company’s investigational RNAi therapeutics focus on Strategic Therapeutic Areas (STArs), including Genetic Medicines, with a pipeline of RNAi therapeutics for the treatment of diseases; Cardio-Metabolic Disease, with a pipeline of RNAi therapeutics toward genetically validated, liver-expressed disease in cardiovascular and metabolic diseases, such as dyslipidemia, hypertension, non-alcoholic steatohepatitis (NASH) and type II diabetes, and Hepatic Infectious Disease, with a pipeline of RNAi therapeutics for the treatment of hepatic infectious diseases.

More notable recent Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) news were published by: Fool.com which released: “Alnylam Pharmaceuticals, Inc. Discloses Deaths, Waits for More Data” on November 04, 2016, also Fool.com with their article: “Better Buy: Alnylam Pharmaceuticals, Inc. vs. Sarepta Therapeutics, Inc.” published on October 10, 2016, Fool.com published: “Alnylam Pharmaceuticals Slid 12.6% Today After Earnings” on November 03, 2016. More interesting news about Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) were released by: Wsj.com and their article: “Alnylam Says Trial of Patisiran Can Continue Following Revusiran Halt” published on October 10, 2016 as well as Globenewswire.com‘s news article titled: “ALNYLAM PHARMACEUTICALS INVESTOR REMINDER: Hagens Berman Reminds Investors in …” with publication date: October 25, 2016.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Tags: , ,

Related posts

Leave a Comment